Home / Pharmaceuticals / Thyroid Gland Disorders Treatment Market By Treatments (Hypothyroidism, Hyperthyroidism) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Thyroid Gland Disorders Treatment Market By Treatments (Hypothyroidism, Hyperthyroidism) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Published: Aug 2016 | Report Code: 58040-08-16

The thyroid gland disorders treatment market is propelling due to the factors such as rise in the patient base suffering from thyroid disorders, rising geriatric population and consistent introduction of innovative and novel therapeutics by market players leading to the growth of the market. Asia Pacific is expected to be the fastest growing market in the thyroid gland disorder treatment market due large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in the countries such as China, India and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.

The report titled “Thyroid Gland Disorders Treatment Market - Growth, Share, Opportunities and Competitive Analysis, 2016–2023” offers strategic insights into the overall thyroid gland disorders treatment market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographical region. The treatment type segment studied for analyzing the overall thyroid gland disorders treatment market are hypothyroidism and hyperthyroidism treatment.  The hypothyroidism treatment includes drugs such as levothroxine and liothyronine, while hyperthyroidism treatments include drugs such as imidazole and propacil. In order to help strategic decision makers, the report also includes competitive profiling of the leading players in thyroid gland disorders treatment market, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the thyroid gland disorders treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global thyroid gland disorders treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global thyroid gland disorders treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in thyroid gland disorders market market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global thyroid gland disorders treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.

Thyroid Gland Disorders Treatment Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Thyroid Gland Disorders Treatment Market Portaiture
2.2 Global Thyroid Gland Disorders Treatment Market, by Treatment, 2015 (USD Mn)
2.3 Thyroid Gland Disorders Treatment Market Share, by Geography, 2015 (Value %)

Chapter 3 Thyroid Gland Disorders Treatment : Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Epidemiology of Thyroid Disorders
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.2 Rising Geriatric Population
3.3.1.3 Government Initiative
3.3.2 Challenges
3.3.2.1 Rising Consumption of Generic Drugs
3.3.3 Opportunities
3.3.3.1 Technological Advancements
3.4 Regulatory Framework
3.5 Attractive Investment Proposition
3.6 Competitive Analysis
3.5.1 Market Share Analysis By Key Players, 2015 (Value %)

Chapter 4 Thyroid Gland Disorders Treatment Market, by Treatments
4.1 Preface
4.2 Hypothyroidism
4.2.1 Levothyroxine
4.2.2 Liothyronine
4.3 Hyperthyroidism
4.3.1 Imidazole
4.3.1 Propacil

Chapter 5 Thyroid Gland Disorders Treatment Market, By Geography
5.1 Overview
5.2 North America
5.2.1. U.S.
5.2.2. Canada
5.3 Europe
5.3.1. U.K.
5.3.2. Germany
5.3.3. Rest of Europe
5.4 Asia Pacific
5.4.1. Japan
5.4.2. China
5.4.3. Rest of Asia Pacific
5.4 Latin America
5.5 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Abbvie, Inc.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Allergan plc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 GlaxoSmithKline plc
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Merck KGaA
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Mylan N.V.
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Novartis AG
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Lannett Company Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Sonofi
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Takeda Pharmaceutical Company Ltd
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
7.11 Other Notable Players

List Of Table :

TABLE 1 Global Thyroid Gland Disoreders Treatment Revenue, by Treatment Type, 2013 – 2023 (USD Mn)
TABLE 2 Global Thyroid Gland Disoreders Treatment Market Revenue, by Geography, 2013 – 2023 (USD Mn)
TABLE 3 North America Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 4 Europe Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 5 Asia - Pacific Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 6 Latin America Thyroid Gland Disoreders Treatment Market Revenue, by Regions, 2013 – 2023 (USD Mn)

List OF Figure :

FIG. 1 Global Thyroid Gland Disoreders Treatment Market, by Treatment, 2015 (USD Mn)
FIG. 2 Global Thyroid Gland Disoreders Treatment Market Share, by Geography, 2015 (Value %)
FIG. 3 Attractive Investment Proposition, Global Thyroid Gland Disoreders Treatment Market, 2015
FIG. 4 Market Share Analysis By Key Players, 2015 (Value %)
FIG. 5 Global Hypothyroidsm Market Revenue, by Drug, 2013 – 2023 (USD Mn)
FIG. 6 Global Levothyroxine Market Revenue, 2013 – 2023 (USD Mn)
FIG. 7 Global Liothyronine Market Revenue, 2013 – 2023 (USD Mn)
FIG. 7 Global Hyperthyroidm Market Revenue, by Drugs, 2013 – 2023 (USD Mn)
FIG. 8 Global Imidazole Market Revenue, 2013 – 2023 (USD Mn)
FIG. 9 Global Propacil Market Revenue, 2013 – 2023 (USD Mn)

Based on the type of treatment the global thyroid gland disorders treatment market is segmented as follows:

  • Hypothyroidism
    • Levothyroxine
    • Liothyronine
  • Hyperthyroidism
    • Imidazole
    • Propacil

Thyroid gland disorder is characterized by underactive or overactive production of thyroid hormones (T3 and T4), termed as hypothyroidism or hyperthyroidism respectively. Thyroid disorders can range from a small, harmless goiter (enlarged gland) that needs no treatment to life-threatening cancer. The most common thyroid problems involve abnormal production of thyroid hormones. Too much thyroid hormone results in a condition known as hyperthyroidism. Insufficient hormone production leads to hypothyroidism. Thyroid gland disorders affect around 5% to 10% of the human population globally. Women are more susceptible to thyroid problems. More than 12 percent of the U.S. population will develop a thyroid condition during their lifetime. An estimated 20 million Americans have some form of thyroid disease. The thyroid gland disorders treatment market is majorly segmented into hypothyroidism and hyperthyroidism treatment.  The hypothyroidism treatment includes drugs such as levothroxine and liothyronine, while hyperthyroidism treatments include drugs such as imidazole and propacil. The thyroid gland disorders treatment market is propelling due to the factors such as rise in the patient base suffering from thyroid disorders, rising geriatric population and consistent introduction of innovative and novel therapeutics by market players leading to the growth of the market.

Thyroid Gland Disorders Treatment Market

For the purpose of this study, the global thyroid gland disorder treatment market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Thyroid Gland Disorders Treatment Market

The geographical segmentation of the global market for thyroid gland disorders treatment market comprises North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. In base year 2015, North America accounted for the largest market in the thyroid gland disorders treatment market due to rising number of patients suffering from thyroid diseases in U.S. According to American Thyroid Association (ASA), more than 12% of the U.S. population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Moreover, mandatory screening of newborns for congenital hypothyroidism, and cost-effective methods to detect thyroid cancer by screening would further expand the thyroid gland disorders treatment market. Rising patient population in the Europe is expected to drive the European thyroid gland disorders treatment market during the forecast period. Asia Pacific is expected to be the fastest growing market in the thyroid gland disorder treatment market due large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in the countries such as China, India and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients